Heber Bio Completes Series C Financing with Over RMB 100 Million Investment from SDIC Capital to Advance Microfluidics Innovation

On December 18, 2020, Hipro Biotechnology Co., Ltd. announced the completion of its Series C financing round, raising over RMB 100 million. Led by SDIC Merchants Investment, this funding will support the industrialization of liquid-phase microfluidic biochip products, accelerate the development of next-generation microfluidic iterations, and advance the company’s marketing channel construction and overseas network expansion.

Hipro, founded in 2006, is a technology-driven enterprise focused on technological innovation in the in vitro diagnostics (IVD) industry. Over the past 14 years, the company has remained grounded in technology, at the forefront of innovation, and committed to originality. It holds 154 patents and has obtained 48 EU CE certifications. Hipro has developed an immunoassay system integrating multiple methodologies, a triple quality control system, and a cloud-based big data platform. Its products are distributed to nearly 10,000 end-user facilities across 60 countries.

In 2012, Hipro pioneered the integrated sampler platform, transforming operational practices in the IVD industry and spearheading the use of single-packaging for liquid-phase reagents. Building on this platform, Hipro has accumulated nearly 40 mature and stable assay items, which have undergone years of market validation and deliver precision comparable to that of central laboratories. In August 2020, after five years of joint development with the University of Freiburg in Germany, Hipro officially launched the diagDx liquid microfluidics platform. Featuring a disruptive “liquid-phase biochip” innovative design concept, this new high-precision, high-throughput detection platform enables rapid diagnostic testing for biochemical immunology, chemiluminescence, molecular diagnostics, and other applications.

Hipro has completed the R&D of its microfluidic products using self-owned funds, achieving high precision through advanced technology. The company now possesses comprehensive manufacturing capabilities spanning from chips to test kits, and from reagents to instruments, enabling perfect cost control through scale and full industry chain integration. Its industrial park, located in China Medical City in Taizhou, Jiangsu Province, covers an area of 53.3 mu. Phase I, completed at the end of 2020, established a 10,000-square-meter microfluidic chip manufacturing facility featuring automated and intelligent GMP-compliant cleanrooms, with a daily production capacity of 250,000 chips. Phase II involves the construction of 53,000 square meters of ancillary cleanroom workshops, aiming to build a global microfluidic chip industrial base and provide production capacity support for the rapid growth of domestic and international markets.

Ren Jian, Executive Director of SDIC Investment Promotionstated: “We consider microfluidics to be a disruptive technology in the industry, with broad market prospects. As a pioneer in China’s POCT market, Hipro possesses extensive experience in industrialization and the technological strength to drive the realization of its goals. With an international perspective and keen insight, Hipro has strategically positioned itself in advance, seizing the initiative in the development of the microfluidics industry and achieving phased results. We believe that, in the process of advancing project industrialization, leveraging the company’s outstanding scientific research and management teams, along with the support of SDIC Capital’s industrial ecosystem, Hipro will fully capitalize on the core competitiveness of its products, achieve leapfrog development, and become a key player in China’s precision diagnostics sector.”

Hao Shushun, Chairman of HiproHe stated: “A company’s prominence stems from its clear positioning and technological advantages. Hipro has a well-defined strategic position and development path. With 15 years of deep engagement in the POCT sector, it has built an integrated solution for clinical settings and customers, ranging from samplers to microfluidic platforms. By integrating technology with market needs and linking innovation with industrial application, Hipro has established an industrial symbiosis system, continuously creating and enhancing value in terms of technical efficiency and cost-effectiveness.”

Microfluidics is a high-potential sector. We are fortunate to have reached consensus with SDIC Investment Promotion on many development directions. With confidence in both industrial growth and technological prowess, we are committed to maximizing the synergy between capital and technology, driving the rapid global adoption of microfluidic technologies through superior product capabilities, and creating greater value for the industry’s advancement.